Role of interleukin-23 as a biomarker in rheumatoid arthritis patients and its correlation with disease activity

Zaky, Doaa Zakaria; El-Nahrery, Eslam

doi:10.1016/j.intimp.2015.12.011

Cited by 38 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are in agreement with other studies [12,14,16] . In contrast with our results, a study by Zaky and El-Nahrery [13] .revealed no significant correlation between IL-23 and disease activity measured by DAS-28. However, these contradictory results may be related to differences among the RA patients as regards to medications administered.…”

Section: Discussioncontrasting

confidence: 99%

“…Our study showed that the level of IL -23 in RA patients was significantly elevated in comparison to healthy controls. This significant elevation in IL-23 level in RA patients was reported by previous studies [12,13,14] . In our study, there was non-significant correlation between each of the age, sex, number of swollen or tender joints and disease duration with IL-23 level.…”

Section: Discussionsupporting

confidence: 87%

“…In our study, there was non-significant correlation between each of the age, sex, number of swollen or tender joints and disease duration with IL-23 level. These results were matched with those of Zaky and El-Nahrery [13] , who did not find correlations between IL-23 and clinical data of patients as duration of the disease and the number of affected joints. In contrast to our results, Fadda et al [12] , found significant correlation between serum IL-23 levels and swollen and tender joints, but not with disease duration in RA patients.…”

Section: Discussionsupporting

confidence: 85%

See 2 more Smart Citations

Role of Interleukin-23 as a Marker of Disease Activity in Rheumatoid Arthritis Patients

Sheikh¹,

El-Shafey²,

Gawish³

et al. 2018

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease. The pathogenesis of RA is mediated by an interdependent network of cytokines which has been extended to include the cytokine, IL-23. IL-23 production appears to be of great importance in the inflammatory reaction in RA. Objectives: We aimed in this study to estimate interleukin-23 (IL-23) level in the sera of rheumatoid arthritis (RA) patients and to determine its relation with disease activity. Subjects and methods: This study was carried out on 40 patients with RA, and 40 healthy control subjects. RA disease activity was measured by 28-joint disease activity score (DAS-28). All patients were subjected to full history taking, thorough clinical examination, radiological and laboratory investigations including c-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti cyclic-citrullinated peptide (anti-CCP) antibodies. Serum IL-23 was measured by enzyme-linked immunosorbent assay (ELISA). Results: In RA patients serum IL-23 level was significantly elevated in comparison to the healthy controls (p<0.001). There was a significant positive correlations between IL-23 level and DAS 28 score. The highest level was detected in patients with high disease activity (p=0.03). There was statistically significant correlation between IL-23 levels and ESR, CRP, RF, anti-CCP antibodies. Conclusion: IL-23 could be a useful marker for disease activity in RA.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Role of Interleukin-23 as a Marker of Disease Activity in Rheumatoid Arthritis Patients

Sheikh¹,

El-Shafey²,

Gawish³

et al. 2018

Zagazig University Medical Journal

View full text Add to dashboard Cite

show abstract

“…Zaky et al . and Michalak‐Stoma et al . observed average IL‐23 levels in healthy subjects to be 33 and 46 pg/mL, respectively.…”

Section: Discussionmentioning

confidence: 91%

Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

Khalilieh

Hodsman²,

et al. 2018

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Tildrakizumab, a high-affinity humanized IgG1k antibody that selectively binds interleukin (IL)-23 p19 subunit of cytokine IL-23 and neutralizes its function, is under investigation for treatment of moderate-to-severe chronic plaque psoriasis. The objective of this analysis was to assess the pharmacokinetics, bioavailability and safety/tolerability of single ascending doses of tildrakizumab after intravenous (IV) and subcutaneous (SC) dosing in healthy subjects. P05661 was a phase 1, single-dose, randomized, placebo-controlled study of tildrakizumab IV doses of 0.1, 0.5, 3 and 10 mg/kg, or placebo. P05776 was a phase 1, single-dose, randomized, placebo-controlled study of tildrakizumab SC doses of 50 or 200 mg, or placebo. After either single IV or SC dosing, tildrakizumab exhibited slow systemic clearance (CL), limited volume of distribution and a long t . Both the C and the area under the curve (AUC) increased proportionally with doses from 0.1 to 10 mg/kg, or 50-200 mg. The bioavailability of SC dosing was ~80% (90% CI: 62-103%) for 50 mg and ~73% (90% CI: 46-115%) for 200 mg, respectively, versus 0.5 and 3 mg/kg IV. Across both studies, six of 43 evaluable subjects were positive for post-dose antidrug antibodies; two of these were positive for neutralizing antibodies. Most adverse events (AEs) were mild; the most frequent AEs included upper respiratory tract infection and headache. Single doses of tildrakizumab 0.1, 0.5, 3 and 10 mg/kg administered IV or single doses of 50 and 200 mg administered SC were safe and well tolerated in healthy adult subjects.

show abstract

“…The inclusion criteria of 22 These non-HLA genes and associations are listed in Table 1. RA, 95 colorectal cancer, 96 Graves' disease, 97 acute myeloid leukemia, 98 PsA and Ps 15,70,71 IL23/TH17 pathway…”

Section: Non -Hl a G Ene S And S Hared G Ene S Involved In Psamentioning

confidence: 99%

Psoriatic arthritis: A systematic review of non‐HLA genetic studies and important signaling pathways

et al. 2020

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory disease that primarily invades the musculoskeletal system and skin. 1 Usually, besides the arthritis damage, including arthritis, enthesitis, dactylitis and axial involvement, patients with PsA have psoriatic skin, such as epidermal hyperplasia, hyperkeratosis, parakeratosis, Munro's microabscesses and mixed dermal infiltrates. 2 In general, the severity of a patient's joint symptoms is consistent with the severity of the skin lesions. 3 In some cases, patients with PsA without psoriatic skin features only have arthritis damage or finger pain, which is similar to rheumatoid arthritis (RA). Generally, only about 13% of patients with PsA have rheumatoid factor in the blood and synovial fluid, while more than 80% of RA patients can be detected with rheumatoid factor. 4 The prevalence of PsA around the world is 0.3%-1%, 4 which differs in race and regions. In Western countries, the prevalence rates are about 0.02%, 0.42% and 0.25% in Sweden, Italy and the USA respectively, 5,6 whereas the rates are relatively lower in the Eastern countries, ranging from 0.01% to 0.1% in China, and <0.00001% in Japan. 6 PsA is not only harmful to an individual's health and life quality, but also may lead to a higher risk to suffer from cardiovascular events. 7 The pathogenesis of PsA is complex, and itmay be caused by genetic and environmental factors. Environmental aspects include infections (eg infectious diarrhea, human immunodeficiency virus infection), smoking, trauma and obesity. 8-11 In the researches for susceptibility genes for PsA, some human leukocyte antigen (HLA) genes are found as risk factors, and some HLA genes are found as protect factors. For instances, HLA-B*38 and HLA-Cw6 alleles are

show abstract

Role of interleukin-23 as a biomarker in rheumatoid arthritis patients and its correlation with disease activity

Cited by 38 publications

References 23 publications

Role of Interleukin-23 as a Marker of Disease Activity in Rheumatoid Arthritis Patients

Role of Interleukin-23 as a Marker of Disease Activity in Rheumatoid Arthritis Patients

Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

Psoriatic arthritis: A systematic review of non‐HLA genetic studies and important signaling pathways

Contact Info

Product

Resources

About